• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

塞尔维亚和黑山不同行政单位人乳头瘤病毒免疫接种第一年实施情况概述

Overview of the Implementation of the First Year of Immunization against Human Papillomavirus across Different Administrative Units in Serbia and Montenegro.

作者信息

Štrbac Mirjana, Joksimović Milko, Vuković Vladimir, Ristić Mioljub, Lončarević Goranka, Kanazir Milena, Nikolić Nataša, Pustahija Tatjana, Rajčević Smiljana, Ljubičić Stefan, Koprivica Marko, Laušević Dragan, Petrović Vladimir

机构信息

Institute of Public Health of Vojvodina, Futoška 121, 21000 Novi Sad, Serbia.

Institute of Public Health of Montenegro, Džona Džeksona bb, 81110 Podgorica, Montenegro.

出版信息

Vaccines (Basel). 2024 Jul 19;12(7):803. doi: 10.3390/vaccines12070803.

DOI:10.3390/vaccines12070803
PMID:39066441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11281365/
Abstract

Despite the availability of a safe and effective vaccination, uptake of human papillomavirus (HPV) vaccination remains low worldwide. We aimed to analyze the coverage of HPV immunization during the first year of the immunization program and the sociodemographic characteristics across different administrative units in Serbia and Montenegro. Coverage of HPV vaccination in Serbia for females aged 9-14 and 15-19 years was 5.5% and 5.9%, respectively. The coverage rate of immunization against HPV in Montenegro for girls aged 9-14 years was 22.1%. Within Serbia, only one administrative region (Moravica) had HPV immunization coverage in girls 9-19 years old above 10%, 11 districts had coverage from 5 to 10%, while 13 districts had coverage below 5%. As per Montenegro, two administrative units, Cetinje and Berane, reported the highest coverage, with 39% and 36.4% of vaccinated eligible girls, respectively. When we explored the coverage of HPV immunization among girls aged 9-19 years across different regions in Serbia, we observed that the level of coverage did not correlate with the number of pediatricians or with the population density. In Montenegro, we observed a similar situation. On the other hand, we noticed a statistically significant moderate negative correlation (r = -0.446; = 0.026) between HPV immunization coverage and the percentage of illiterate women in the administrative units. Comparing the coverage between the two countries we found that the higher coverage in Montenegro corresponded with a smaller number of female populations aged 9-14 years, with higher average net monthly income, with smaller population density and smaller number of pediatricians, among divorced persons, and among those without formal education or incompletely primary education. Taking into account the experiences in Montenegro, increasing immunization coverage in Serbia could be achieved through a more vigorous educational campaign targeting schools, the general population, and healthcare workers as well as by additionally incentivizing those engaged in these activities.

摘要

尽管有安全有效的疫苗可用,但全球人乳头瘤病毒(HPV)疫苗的接种率仍然很低。我们旨在分析免疫规划第一年期间HPV免疫接种的覆盖率以及塞尔维亚和黑山不同行政单位的社会人口特征。塞尔维亚9至14岁和15至19岁女性的HPV疫苗接种率分别为5.5%和5.9%。黑山9至14岁女孩的HPV免疫接种率为22.1%。在塞尔维亚境内,只有一个行政区(莫拉维察)9至19岁女孩的HPV免疫接种率高于10%,11个区的接种率为5%至10%,而13个区的接种率低于5%。在黑山,两个行政单位,采蒂涅和贝拉内,报告的接种率最高,分别有39%和36.4%符合条件的女孩接种了疫苗。当我们探究塞尔维亚不同地区9至19岁女孩的HPV免疫接种覆盖率时,我们发现覆盖率水平与儿科医生数量或人口密度无关。在黑山,我们也观察到了类似情况。另一方面,我们注意到HPV免疫接种覆盖率与各行政单位文盲女性百分比之间存在统计学上显著的中度负相关(r = -0.446;P = 0.026)。比较两国的接种率,我们发现黑山较高的接种率与9至14岁女性人口数量较少、平均月净收入较高、人口密度较小、儿科医生数量较少、离婚人群以及未接受正规教育或小学未完成教育人群有关。考虑到黑山的经验,塞尔维亚可以通过针对学校、普通民众和医护人员开展更有力的教育活动,以及额外激励参与这些活动的人员来提高免疫接种覆盖率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/0e0e1e4db2ab/vaccines-12-00803-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/85f9a4c9133d/vaccines-12-00803-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/c9fbfac8518b/vaccines-12-00803-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/4e20797f81e1/vaccines-12-00803-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/0e0e1e4db2ab/vaccines-12-00803-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/85f9a4c9133d/vaccines-12-00803-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/c9fbfac8518b/vaccines-12-00803-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/4e20797f81e1/vaccines-12-00803-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0369/11281365/0e0e1e4db2ab/vaccines-12-00803-g004.jpg

相似文献

1
Overview of the Implementation of the First Year of Immunization against Human Papillomavirus across Different Administrative Units in Serbia and Montenegro.塞尔维亚和黑山不同行政单位人乳头瘤病毒免疫接种第一年实施情况概述
Vaccines (Basel). 2024 Jul 19;12(7):803. doi: 10.3390/vaccines12070803.
2
Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.在马拉维实施人乳头瘤病毒疫苗示范项目:成功经验与挑战
BMC Public Health. 2017 Jun 26;17(1):599. doi: 10.1186/s12889-017-4526-y.
3
National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.坦桑尼亚全国推广人乳头瘤病毒(HPV)疫苗:政策决策与实施。
Vaccine. 2022 Mar 31;40 Suppl 1(Suppl 1):A2-A9. doi: 10.1016/j.vaccine.2021.04.025. Epub 2021 May 4.
4
Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.基于社区的家庭人乳头瘤病毒(HPV)疫苗接种覆盖率和可接受性评估 - HPV 疫苗示范项目,柬埔寨 - 2017 年。
Vaccine. 2019 Feb 21;37(9):1202-1208. doi: 10.1016/j.vaccine.2018.12.052. Epub 2019 Jan 24.
5
Knowledge about HPV Infection and the HPV Vaccine among Parents in Southeastern Serbia.HPV 感染和 HPV 疫苗在塞尔维亚东南部父母中的认知。
Medicina (Kaunas). 2022 Nov 22;58(12):1697. doi: 10.3390/medicina58121697.
6
Parental perspective on human papillomavirus (HPV) vaccination in Serbia: Knowledge, attitudes and practice.塞尔维亚父母对人乳头瘤病毒(HPV)疫苗接种的看法:知识、态度与实践
Sex Reprod Healthc. 2018 Jun;16:192-198. doi: 10.1016/j.srhc.2018.04.010. Epub 2018 Apr 17.
7
An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.赞比亚人乳头瘤病毒(HPV)疫苗接种成本评估。
BMC Infect Dis. 2024 Apr 2;24(1):369. doi: 10.1186/s12879-024-09222-2.
8
Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019.人类乳头瘤病毒(HPV)疫苗在锡金邦的引入:印度首个全州多年龄组 HPV 疫苗引入(2018-2019 年)的最佳实践。
Vaccine. 2022 Mar 31;40 Suppl 1(Suppl 1):A17-A25. doi: 10.1016/j.vaccine.2021.07.024. Epub 2021 Aug 22.
9
Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.卢旺达的人乳头瘤病毒疫苗接种率:按出生队列进行的人群水平分析。
Vaccine. 2020 May 19;38(24):4001-4005. doi: 10.1016/j.vaccine.2020.04.021. Epub 2020 Apr 24.
10
Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.全球人乳头瘤病毒疫苗接种覆盖率的估计:国家层面指标分析。
BMJ Open. 2021 Sep 2;11(9):e052016. doi: 10.1136/bmjopen-2021-052016.

引用本文的文献

1
Impact of health promotion strategies on HPV vaccination uptake: A descriptive epidemiological study (2019-2024).健康促进策略对人乳头瘤病毒疫苗接种率的影响:一项描述性流行病学研究(2019 - 2024年)
PLoS One. 2025 Sep 4;20(9):e0331592. doi: 10.1371/journal.pone.0331592. eCollection 2025.
2
Knowledge and Attitudes Regarding Human Papillomavirus Vaccination Among Future Healthcare Workers in Serbia.塞尔维亚未来医护人员对人乳头瘤病毒疫苗接种的认知与态度
Vaccines (Basel). 2024 Dec 26;13(1):11. doi: 10.3390/vaccines13010011.
3
Relationship Between Population Density, Availability of Gynecological Services, and Cervical Cancer Incidence and Mortality Across Administrative Units in Serbia and Bosnia and Herzegovina During 2016-2020.

本文引用的文献

1
Prevalence of Carcinogenic Genotypes of HPV-Infected Women in a Ten-Year Period (2014-2023) in Vojvodina, Serbia.塞尔维亚伏伊伏丁那地区 HPV 感染女性在十年间(2014-2023 年)致癌基因型的流行率。
Medicina (Kaunas). 2024 Jun 1;60(6):922. doi: 10.3390/medicina60060922.
2
Socioeconomic inequalities in vaccine uptake: A global umbrella review.疫苗接种方面的社会经济不平等:全球伞式综述。
PLoS One. 2023 Dec 13;18(12):e0294688. doi: 10.1371/journal.pone.0294688. eCollection 2023.
3
Factors influencing human papillomavirus vaccination uptake in European women and adolescents: A systematic review and meta-analysis.
2016 - 2020年塞尔维亚和波斯尼亚和黑塞哥维那各行政单位人口密度、妇科服务可及性与宫颈癌发病率和死亡率之间的关系
Medicina (Kaunas). 2024 Dec 2;60(12):1987. doi: 10.3390/medicina60121987.
影响欧洲女性和青少年人乳头瘤病毒疫苗接种率的因素:系统评价和荟萃分析。
Psychooncology. 2024 Jan;33(1):e6242. doi: 10.1002/pon.6242. Epub 2023 Nov 6.
4
Motives and attitudes of parents toward HPV vaccination: Results from the initial period of HPV vaccine rollout in Serbia.家长对 HPV 疫苗接种的动机和态度:塞尔维亚 HPV 疫苗推广初期的结果。
PLoS One. 2023 Jul 6;18(7):e0287295. doi: 10.1371/journal.pone.0287295. eCollection 2023.
5
E6/E7 mRNA Expression of the Most Prevalent High-Risk HPV Genotypes in Cervical Samples from Serbian Women.塞尔维亚女性宫颈样本中最常见的高危型人乳头瘤病毒基因型的E6/E7信使核糖核酸表达
Diagnostics (Basel). 2023 Feb 28;13(5):917. doi: 10.3390/diagnostics13050917.
6
Vaccine Hesitancy: Obstacles and Challenges.疫苗犹豫:障碍与挑战
Curr Pediatr Rep. 2022;10(4):241-248. doi: 10.1007/s40124-022-00278-9. Epub 2022 Oct 8.
7
Distribution of vaccine-related high-risk human papillomaviruses and their impact on the development of cervical dysplasia in women in Montenegro.黑山共和国女性中疫苗相关高危人乳头瘤病毒的分布及其对宫颈发育异常的影响
Acta Microbiol Immunol Hung. 2021 Nov 1. doi: 10.1556/030.2021.01606.
8
Sociodemographic Correlates of Human Papillomavirus Vaccine Uptake: Opportunistic and Catch-Up Vaccination in Norway.人乳头瘤病毒疫苗接种的社会人口学关联因素:挪威的机会性接种和补种
Cancers (Basel). 2021 Jul 12;13(14):3483. doi: 10.3390/cancers13143483.
9
HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019.HPV 疫苗接种在全球范围内的推广情况以及世卫组织和儿基会对 2010-2019 年各国 HPV 免疫接种覆盖率的估计。
Prev Med. 2021 Mar;144:106399. doi: 10.1016/j.ypmed.2020.106399. Epub 2020 Dec 31.
10
Factors Associated with HPV Vaccination Uptake and HPV-Associated Cancers: A County-Level Analysis in the State of Alabama.与 HPV 疫苗接种率和 HPV 相关癌症相关的因素:阿拉巴马州的县级分析。
J Community Health. 2019 Dec;44(6):1214-1223. doi: 10.1007/s10900-019-00690-1.